Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Aug 16, 2021 9:00am EDT

CohBar Appoints Carol Nast to Its Board of Directors

Aug 10, 2021 4:04pm EDT

CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update

Aug 10, 2021 4:02pm EDT

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

Aug 04, 2021 4:05pm EDT

CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021

Jul 14, 2021 9:00am EDT

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Jun 10, 2021 9:00am EDT

CohBar to Present at the BIO 2021 Digital Conference

May 17, 2021 4:02pm EDT

CohBar Reports First Quarter 2021 Financial Results and Provides Business Update

May 03, 2021 9:00am EDT

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

Apr 27, 2021 8:30am EDT

CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

Apr 21, 2021 9:00am EDT

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity